Biotech Values

[mcbio]

ALNY’s phase-2b data for ALN-RSV01 misses primary endpoint on ITT basis, but hits on LOCF and PP calculations:

finance.yahoo.com/news/alnylam-announces-top-line-results-100000007.html

The stock is little changed today. Did anyone here listen to the CC?

I haven't yet, but, at first blush, data seems encouraging given so narrow of a miss on ITT coupled with hitting on LOCF and PP. At a minimum, seems like this data would be good enough to warrant continued testing of the drug.